RESEARCH-USE BIOSIMILAR ANTIBODY
Rilotumumab
Monoclonal antibody · IgG2
Rilotumumab (AMG 102) is an anti-HGF (anti-hepatocyte growth factor) monoclonal antibody, inhibits HGF/MET-driven signaling. Rilotumumab shows anti-tumor activity, and can be used in castration-resistant prostate cancer (CRPC) and solid tumor research.
TARGETHGF
YMonoclonal antibody
CATALOGSC-BS-219
CATALOG NUMBERSC-BS-219
MOLECULAR WEIGHTApprox. 145.2 kDa
PRODUCT FORMATMonoclonal antibody
PRODUCT OVERVIEW
A research-use configuration for comparative antibody studies
Rilotumumab (AMG 102) is an anti-HGF (anti-hepatocyte growth factor) monoclonal antibody, inhibits HGF/MET-driven signaling. Rilotumumab shows anti-tumor activity, and can be used in castration-resistant prostate cancer (CRPC) and solid tumor research.
Rilotumumab is a recombinant research-use antibody directed against HGF.